Drugs / BL22
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00126646 | Jun 2005 → Mar 2009 | leukemia, lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00021983 | Dec 1998 → ? | leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00924040 | Feb 2009 → Aug 2010 | hairy cell leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00074048 | Oct 2003 → Apr 2007 | leukemia | MedImmune LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00077493 Comparator | Jan 2004 → Oct 2008 | leukemia, lymphoma | MedImmune LLC | Suspended | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00077493 ↗ |
| Known as | CAT-3888 | “BL22, also called CAT-3888 or RFB4(dsFv)-PE38, is a recombinant immunotoxin containing an Fv fragment of an anti-CD22 monoclonal antibody and truncated Pseudomonas exotoxin (PE).” NCT00924040 ↗ |
| Known as | RFB4(dsFv)-PE38 | “BL22, also called CAT-3888 or RFB4(dsFv)-PE38, is a recombinant immunotoxin containing an Fv fragment of an anti-CD22 monoclonal antibody and truncated Pseudomonas exotoxin (PE).” NCT00924040 ↗2“RFB4(dsFv)-PE38 (BL22), a recombinant immunotoxin containing an anti-CD22 variable domain (Fv) fused to truncated pseudomonas exotoxin” PMID 11474661 ↗ Jul 2001 “Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.” PMID 16061911 ↗ Aug 2005 |
| Action | Deplete | “The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells.” NCT00074048 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant immunotoxin containing an anti-CD22 variable domain (Fv) fused to truncated pseudomonas exotoxin” PMID 11474661 ↗ Jul 2001 |
| Route | Intravenous | “Patients receive recombinant BL22 immunotoxin IV over 30 minutes” NCT00021983 ↗ |
| Target | CD22 | “an anti-CD22 variable domain (Fv)” PMID 11474661 ↗ Jul 2001 |